© 2016, The Author(s). Pulmonary arterial hypertension (PAH) is a chronic and progressive disease which continues to carry an unacceptably high mortality and morbidity. The nitric oxide (NO) pathway has been implicated in the pathophysiology and progression of the disease. Its extremely short half-life and systemic effects have hampered the clinical use of NO in PAH. In an attempt to circumvent these major limitations, we have developed a new NO-nanomedicine formulation. The formulation was based on hydrogel-like polymeric composite NO-releasing nanoparticles (NO-RP). The kinetics of NO release from the NO-RP showed a peak at about 120 min followed by a sustained release for over 8 h. The NO-RP did not affect the viability or inflammation responses of endothelial cells. The NO-RP produced concentration-dependent relaxations of pulmonary arteries in mice with PAH induced by hypoxia. In conclusion, NO-RP drugs could considerably enhance the therapeutic potential of NO therapy for PAH.
Mohamed, N. A., Ahmetaj-Shala, B., Duluc, L., Mackenzie, L. S., Kirkby, N. S., Reed, D. M., … Yacoub, M. H. (2016). A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension. Journal of Cardiovascular Translational Research, 9(2), 162–164. https://doi.org/10.1007/s12265-016-9684-2